Drug interactions
Ethinyl estradiol-norgestimate + Larotrectinib
Severity: Minor
Ethinyl estradiol-norgestimate and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate and a weak inhibitor of CYP3A4 in vitro. Any increase in ethinyl estradiol exposure is expected to be small and unlikely to be clinically important.
What this interaction means in plain words
Ethinyl estradiol-norgestimate and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Ethinyl estradiol-norgestimate belongs to Endocrine; Larotrectinib belongs to Oncology.
Why it happens
Possible weak inhibition of CYP3A4-mediated metabolism of ethinyl estradiol; the effect is theoretical.
What to do
No routine change is needed. Monitor for estrogen-related adverse effects such as nausea, breast tenderness or headache.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ethinyl estradiol-norgestimate and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ethinyl estradiol-norgestimate
- Ethinyl estradiol-norgestimate + Fezolinetant Contraindicated
- Ethinyl estradiol-norgestimate + Ombitasvir / paritaprevir / ritonavir and dasabuvir Contraindicated
- Ethinyl estradiol-norgestimate + Tranexamic acid Contraindicated
- Aminocaproic acid + Ethinyl estradiol-norgestimate Major
- Amobarbital + Ethinyl estradiol-norgestimate Major
- Anastrozole + Ethinyl estradiol-norgestimate Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Ethinyl estradiol-norgestimate with Larotrectinib?
MediHelp rates the interaction as minor. Ethinyl estradiol-norgestimate and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate and a weak inhibitor of CYP3A4 in vitro. Any increase in ethinyl estradiol exposure is expected to be small and unlikely to be clinically important.
How serious is the interaction between Ethinyl estradiol-norgestimate and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine change is needed. Monitor for estrogen-related adverse effects such as nausea, breast tenderness or headache.
What other medicines interact with Ethinyl estradiol-norgestimate?
MediHelp also lists interactions of Ethinyl estradiol-norgestimate with, for example, Fezolinetant, Ombitasvir / paritaprevir / ritonavir and dasabuvir, Tranexamic acid. The full list is on the Ethinyl estradiol-norgestimate page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
